The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
Yonsei Medical Journal 2010³â 51±Ç 1È£ p.1 ~ p.8
Á¶º´Ã¶(Cho Byoung-Chul) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÁÖÇ×(Kim Joo-Hang) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
(Soo Ross-A) - National University of Singapore and Cancer Science Institute of Singapore National University Hospital
(Yang Chih-Hsin) - National Taiwan University College of Medicine Graduate Institute of Oncology
Abstract
The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.
Å°¿öµå
Non-small cell lung cancer, chemotherapy, monoclonal antibody, bevacizumab, cetuximab
KMID :
0311120100510010001
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Both bevacizumab and cetuximab are also likely to work in Asian patients with advanced NSCLC.